Skip to main content
Clinical Trials/NCT05790330
NCT05790330
Recruiting
N/A

'Mind and Skin': A Prospective Cohort Study Evaluating the Impact of Inflammation, Itch and Sleep Disturbance on the Brain, Mental Health and Cognition, in Patients With Severe Atopy

King's College London1 site in 1 country90 target enrollmentMarch 10, 2023

Overview

Phase
N/A
Intervention
Methotrexate
Conditions
Atopic Dermatitis
Sponsor
King's College London
Enrollment
90
Locations
1
Primary Endpoint
Metabolome swab
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

'Mind and Skin': A prospective cohort study evaluating the impact of inflammation, itch and sleep disturbance on the brain, mental health and cognition, in patients with severe atopy.

Detailed Description

Atopic eczema is an intensely itchy skin disease which often starts in infancy or early childhood. It can have profound effects on patients' quality of life and cause long-lasting psychological impairment. Sleep may be very disturbed. More severe disease often requires oral/injectable immuno-modulatory treatments (i.e. medications which control symptoms by influencing the immune system). There is an association between eczema, impaired cognitive functioning and mental health disorders, but the underlying mechanisms are not clearly defined. This projects examines the links between inflammation-driven itching and disturbed sleep, and how this might be causally responsible for systemic and brain inflammation, disturbance of cognitive functioning and mental health problems. The investigators will also study potential changes occurring following an improvement in eczema when patients are treated with systemic immuno-modulators. Key investigations will include: i) Home-based sleep studies using a commercially available sleep devices (for example DREEM headband, Philips Actiwatch, oximetry) ii) Structural and functional magnetic resonance imaging (MRI) of the brain, iii) Blood tests to quantify systemic inflammation iv) Genetic analyses, particularly related to the immune system, circadian rhythm (the "internal 24-hour clock"), skin barrier function and the risk of developing eczema or associated diseases, v) Assessments of the skin's barrier function vi) Stool samples and skin swabs to study the gut and skin microbiome. The investigators will utilise existing anonymised data for comparative purposes (e.g. from patients with Attention Deficit Hyperactivity Disorder (ADHD) and healthy controls who previously had brain imaging.) The investigators will explore eczema patients' and families' perception of their disease, in particular itch and the resulting sleep loss, through focus groups, to better understand the sociological impact of eczema, and how these patients' interactions with the external world and society are affected by eczema. Importantly, this will include exploration of family dynamics, as patients with eczema often have profound sleep disturbance from early life, which can impact on their caregivers' sleep and quality of life.

Registry
clinicaltrials.gov
Start Date
March 10, 2023
End Date
June 1, 2027
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients aged 12 to 18 with atopic eczema (groups 1 and 2), which has been diagnosed by a Consultant Dermatologist.
  • Patients with atopic eczema warranting systemic immuno-modulatory therapy or patients with atopic eczema on topical therapy or healthy controls.
  • Written informed consent for study participation obtained from the patient or from the parent(s) / legal guardian, with assent as determined by the patient's age and level of understanding.
  • Willingness to comply with all study requirements.
  • Competent use of English language, according to patient's age (patients will be required to understand the written questionnaires and complying with instructions during MRI scanning).

Exclusion Criteria

  • Insufficient understanding of the study by the patient and/or parent/guardian.
  • Any clear contra-indication to MRI scanning. In particular this would be due to the presence of any implanted devices or metal from previous surgery or accident. This would be fully assessed with a standardised safety questionnaire by a radiographer prior to MRI scanning.
  • Any condition deemed by the Investigator to limit a patient's ability to undertake MRI components of the study, for example significant claustrophobia.
  • Diagnosed by a sleep medicine specialist with a formal sleep disorder, requiring systemic medication.
  • Sleep disturbance from co-morbid illness (including physical and/or mental/psychological illness) other than atopic eczema, deemed by the Investigator to significantly impact on sleep components of the study.
  • Previous and/or current substance misuse.
  • Patients who take medications that would, in the investigator's opinion, impact on quality of sleep studies.

Arms & Interventions

Severe eczema

Patients aged 12-18 who have been diagnosed with atopic eczema and require starting systemic therapy.

Intervention: Methotrexate

Severe eczema

Patients aged 12-18 who have been diagnosed with atopic eczema and require starting systemic therapy.

Intervention: Dupilumab

Outcomes

Primary Outcomes

Metabolome swab

Time Frame: 6 months

Skin metabalome analysis using a skin swab

Eczema Area and Severity Index (EASI) Score

Time Frame: 6 months

Clinical assessment of atopic dermatitis disease activity. Range 0-72 (72 being the most severe outcome)

Transepidermal water loss (TEWL)

Time Frame: 6 months

Skin barrier function measurement using a device which measures the amount of water that passively evaporates through skin to the external environment due to water vapor pressure gradient on both sides of the skin barrier

Peak Pruritus Numerical Rating Score

Time Frame: 6 months

Patient reported itch severity. Range 0-10 (10 being the worst outcome)

Skin surface pH

Time Frame: 6 months

Skin barrier function measurement using a pH measuring device.

Skin ELISA (enzyme-linked immunosorbent assay) and serum ELISA

Time Frame: 6 months

Immunoassay detection and quantification

RNA sequencing of blood serum

Time Frame: 6 months

To detect transcript isoforms, gene fusions and single nucleotide variants.

Pediatric Sleep Questionnaire

Time Frame: 6 months

Sleep questionnaire. Score 18-126 (126 being the worst clinical outcome)

Morningness-Eveningness Questionnaire

Time Frame: 6 months

Sleep questionnaire. Score 16-86 assesses individual differences in morningness and eveningness - the degree to which respondents are active and alert at certain times of day.

Patient-Reported Outcomes Measurement Information System (PROMIS)

Time Frame: 6 months

Sleep questionnaire. Score 0-20 (0 being the worst clinical outcome)

Pittsburgh Sleep Quality Index

Time Frame: 6 months

Sleep questionnaires. Score 0-21 (21 being the worst clinical outcome)

Dreem headband electroencephalogram monitoring

Time Frame: 6 months

Sleep study - Measures brain activity to assess sleep cycles

Polysomnography

Time Frame: 6 months

Sleep study incorporating electroencephalogram, electro-oculogram, electromyogram, electrocardiogram, and pulse oximetry, as well as airflow and respiratory effort, to evaluate for underlying causes of sleep disturbances.

Actigraphy Watch analysis

Time Frame: 6 months

Watch is worn by participant which records movement during sleep to analyse sleep pattern

EMFIT mattress analysis

Time Frame: 6 months

Mattress sensor which records movement during sleep to analyse sleep pattern to analyse sleep pattern

Wechsler Abbreviated Scale of Intelligence Second Edition (WASI-II) Score

Time Frame: 6 months

Intelligence Quotient Test. Score 40-160 (40 being the worst clinical outcome)

Go/No-GO Task

Time Frame: 6 months

The Go/No-go task requires participants to respond by pressing a button when they see a "go" signal, and not respond when they see the "no-go" signal. The key behaviour measured with this experiment is the participants' ability to withhold a response on No-go trials. This is scored as a fraction of correct responses.

Simon Task

Time Frame: 6 months

In this task participants are asked to respond to visual stimuli by making a rightward response to one stimulus (e.g. a circle) and a leftward response to another (e.g. a square). This is scored as a fraction of correct responses.

Continuous Performance Task

Time Frame: 6 months

In this task participants are asked to only respond to a specific sequence of visual stimuli. This is scored as a fraction of correct responses.

Time Discrimination Task

Time Frame: 6 months

In this task participants are ask to decide which stimuli stayed on screen for the longest duration. This is scored as a fraction of correct responses.

Vigilance Task (Mackworth Clock)

Time Frame: 6 months

In this task participants are asked to watched a clock hand that moves every second around the clock. From time to time the hand skips a second and participants need to respond to this. This is scored as a fraction of correct responses.

Performance on Working Memory Task

Time Frame: 6 months

Completed in functional MRI

Performance on Sustained Attention Task

Time Frame: 6 months

Completed in functional MRI

Resting Brain State

Time Frame: 6 months

Measured in functional MRI

Structural Changes in the Brain

Time Frame: 6 months

Structure of the brain is measured in MRI

Study Sites (1)

Loading locations...

Similar Trials